Phil Leighton, PhDDirector of Molecular Biology at Ligand Pharmaceuticals
Dr. Leighton is Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University, followed by post-doctoral studies at the University of California, San Francisco. At Ligand, he has been responsible for the development and validation of lines of transgenic chickens used for the discovery of human antibodies. The original transgenic platform, OmniChickenTM, has been used for antibody discovery programs by pharmaceutical industry partners since 2016. More recently, he has developed the OmniClic line, which can be used for discovery of antibodies with a common light chain for bispecific antibody development.